The IMA Group announced on October 8 the acquisition of Chicago Research Center (CRC), an independent clinical research site based in Chicago, Illinois.
Founded in 2005, CRC is known for its expertise in Phase I–IV trials, focused on the central nervous system, sleep disorders, mood and memory disorders, pain and general medicine. The company operates a research sleep lab for dedicated use in insomnia, apnea, narcolepsy, restless leg and shift work sleep disorder clinical trials.
The IMA Group provides government workers with medical, psychological and related evaluations, as well as ancillary services, assists payers with case management and occupational health management solutions and offers clinical research firms access to new advances in pharmacology and biotechnology for research subjects. IMA is backed by Centre Partners, a lower middle-market private equity firm focused on the healthcare, consumer and commercial services sectors.
CRC will continue operating under its current name and leadership, with its team of investigators and staff remaining in place, led by President and CEO Stacy Malm, MS, LCPC. The move also marks IMA Clinical Research’s first foray into sleep research. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 63rd Life Sciences R&D acquisition of the year, and the 17th in the clinical trials specialty. There were 27 clinical trial deals announced in 2024, and 42 announced in 2023.
